Schering Continues To Feel Symptoms From Claritin Switch With Net Loss
This article was originally published in The Tan Sheet
Executive Summary
Sales of Schering-Plough's OTC Claritin (loratadine) allergy drug rebounded from a poor second quarter but the impact of the switch from Rx status continued to drag down the firm's overall earnings
You may also be interested in...
Wyeth Sees Alavert Sales Decline In Fourth Quarter Despite Good Year
Sales for Wyeth's Alavert (loratadine) totaled $81.6 mil. in 2003, its first full year on the market, following a significant drop in the fourth quarter
Claritin Hives Relief Approval Could Close Out Rx Product Line
Schering-Plough will not be granted marketing exclusivity for its OTC Claritin Hives Relief,following FDA approval Nov. 19
Allegra Sales Decline Will Not Prompt OTC Switch, Aventis Says
Decreasing Allegra sales in the face of increased competition from OTC antihistamines will not lead Aventis to pursue a switch for the drug, the firm stated during an Oct. 30 call on third-quarter results